Navigation
-
Advaxis to Receive $1.6 Million Through New Jersey Technology Business Tax (NOL) Program
-
Advaxis Presents New Data Featuring Its Lm Technology™ at the Society for Immunotherapy of Cancer 2015 Annual Meeting
-
Advaxis to Present at the Jefferies Autumn 2015 Global Healthcare Conference
-
Advaxis Provides Additional Information on Clinical Hold
-
Advaxis Launches MINE(TM) Collaboration
-
Advaxis’s Cancer Immunotherapies to be Featured in Three Poster Presentations at the 2015 SITC Annual Meeting
-
Advaxis Reports Clinical Hold of Investigational Agent Axalimogene Filolisbac
-
First Human Patient Treated in Phase 1b Study of Advaxis's ADXS-HER2 in HER2 Expressing Solid Tumors
-
Advaxis's Axalimogene Filolisbac (ADXS-HPV) Showed 38.5 Percent 12-Month Survival in Patients With Persistent/Recurrent Metastatic Cervical Cancer
-
FDA Awards Grant for Phase 2 Study of Axalimogene Filolisbac (ADXS-HPV) in HPV-Associated Head and Neck Cancer
